Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC)

被引：1
|
作者：
Chen, Zhendong
Bai, Yuxian
Zhang, Tao
Ying, Jieer
Lin, Xiaoyan
Yang, Liu
Wang, Jun
Zhang, Juan
Yu, Fan
Fei, Cong
Huang, Ruiqi
Li, Jin
机构：
[1] Anhui Med Hosp, Second Hosp, Hefei, Peoples R China
[2] Harbin Med Univ Canc Hosp, Harbin, Peoples R China
[3] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[4] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[5] Fujian Med Univ Union Hosp, Fuzhou, Peoples R China
[6] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China
[7] BeiGene Beijing Co Ltd, Beijing, Peoples R China
[8] BeiGene Beijing Co Ltd, Shanghai, Peoples R China
[9] Shanghai East Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.281
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
281
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC)
    Zhang, Feng
    Bai, Yuxian
    Fang, Weijia
    Meng, Zhiqiang
    Xiong, Jianping
    Guo, Yabing
    Zhang, Tao
    Zhang, Jingdong
    Ying, Jieer
    Chen, Zhendong
    Ren, Zhenggang
    Chen, Yajin
    Hao, Chunyi
    Yang, Liu
    Wang, Jun
    Zhang, Juan
    Yu, Fan
    Fei, Cong
    Wu, Xikun
    Qin, Shukui
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [2] Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)
    Goh, J. C.
    Coward, J.
    Gao, B.
    Da Silva, I. Pires
    Voskoboynik, M.
    Day, D.
    Body, A.
    Gan, H. K.
    Li, X.
    Sun, J.
    Fei, C.
    Yang, L.
    Millward, M.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1446 - S1447
  • [3] The safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with locally recurrent or metastatic triple-negative breast cancer.
    Fan, Lei
    Liu, Xiyu
    Jin, Xi
    Yang, Yunsong
    Chen, Li
    Hu, Xin
    Wang, Zhonghua
    Jiang, Yizhou
    Shao, Zhimin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC).
    Goh, Jeffrey
    Coward, Jermaine
    Gao, Bo
    da Silva, Ines P.
    Voskoboynik, Mark
    Day, Daphne
    Body, Amy L.
    Gan, Hui K.
    Chen, Cheng
    Xiang, Xiao
    Fei, Cong
    Yang, Liu
    Millward, Michael
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [5] Phase (Ph) I/II study of sitravatinib (Sitra) alone or with tislelizumab (TIS) in advanced hepatocellular carcinoma (HCC) and gastric/gastroesophageal junction cancer (GC/ GEJC)
    Li, J.
    Bai, Y.
    Chen, Z.
    Ying, J.
    Guo, Y.
    Fang, W.
    Zhang, F.
    Xiong, J.
    Zhang, T.
    Meng, Z.
    Zhang, J.
    Yu, F.
    Zhang, J.
    Zhang, Z.
    Qin, S.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S595 - S596
  • [6] Safety/tolerability and preliminary antitumour activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC)
    Goh, Jeff
    Coward, Jermaine
    Gao, Bo
    da Silva, Ines Pires
    Voskoboynik, Mark
    Day, Daphne
    Body, Amy Louise
    Gan, Hui K.
    Chen, Cheng
    Xiang, Xiao
    Fei, Cong
    Yang, Liu
    Millward, Michael
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 65 - 65
  • [7] Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
    Bai, Y.
    Xu, N.
    Yuan, X.
    Wang, B.
    Li, E.
    Li, X.
    Li, Y.
    Wang, X.
    Yang, S.
    Xu, J.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [8] Adjuvant chemoradiotherapy in patients (pts) with resectable gastric (GC) or gastroesophageal junction cancer (GEJC): A monoinstitutional experience
    Soini, Barbara
    Pani, Giuseppe
    Caffo, Orazio
    Frisinghelli, Michela
    Veccia, Antonello
    Brugnara, Sonia
    Caldara, Alessia
    DiPasquale, MariaChiara
    Ferro, Antonella
    Mussari, Salvatore
    Murgia, Viviana
    Russo, Lucianna
    Valduga, Francesco
    Tumulo, Salvatore
    Galligioni, Enzo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] DIRECT AND INDIRECT COSTS ASSOCIATED WITH UNRESECTABLE ADVANCED OR METASTATIC (ADV/MET) GASTRIC CANCER (GC), GASTROESOPHAGEAL JUNCTION CANCER (GEJC) AND ESOPHAGEAL ADENOCARCINOMA (EAC) FOR PATIENTS AND THEIR CAREGIVERS
    Hall, J.
    Khela, K.
    Bertwistle, D.
    Xiao, H.
    [J]. VALUE IN HEALTH, 2020, 23 : S482 - S483
  • [10] The humanistic burden reported by patients with unresectable locally advanced or metastatic (adv/met) gastric cancer (GC), gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): An international real-world survey
    Hall, J. P.
    Khela, K.
    Moon, R.
    Middleton-Dalby, C.
    Bertwistle, D.
    Xiao, H.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S918 - S918
12345